Mark R. Gilbert
National Institutes of Health · 970 works · 49,800 citations · h-index 104
Top works
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- Sequences of taxol and cisplatin: a phase I and pharmacologic study.
- Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups
- Correlation of O 6 -Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity
- Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
- Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
- Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions
- Phase III Study Comparing Three Cycles of Infusional Carmustine and Cisplatin Followed by Radiation Therapy With Radiation Therapy and Concurrent Carmustine in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme: Eastern Cooperative Oncology Group Trial 2394
- Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
- Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous System
- Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
- Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
- Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
- Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials
- IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas
- Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients
- Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001
- A multigene predictor of outcome in glioblastoma
- Challenges to curing primary brain tumours